Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.

Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease.

Previously, we demonstrated that allopregnanolone (APα) promoted proliferation of rodent and human neural progenitor cells in vitro. Further, we demonstrated that APα promoted neurogenesis in the hippocampal subgranular zone (SGZ) and reversed learning and memory deficits in the male triple transgen...

Full description

Bibliographic Details
Main Authors:	Shuhua Chen, Jun Ming Wang, Ronald W Irwin, Jia Yao, Lifei Liu, Roberta Diaz Brinton
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21918687/?tool=EBI

Similar Items

Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease.
by: Ronald W Irwin, et al.
Published: (2015-01-01)

Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders
by: Ronald W. Irwin, et al.
Published: (2014-07-01)

Allopregnanolone pleiotropic action in neurons and astrocytes: calcium signaling as a unifying mechanism
by: Tian Wang, et al.
Published: (2023-12-01)

Allopregnanolone: Regenerative therapeutic to restore neurological health
by: Gerson D. Hernandez, et al.
Published: (2022-11-01)

Correction: Allopregnanolone Preclinical Acute Pharmacokinetic and Pharmacodynamic Studies to Predict Tolerability and Efficacy for Alzheimer's Disease.
by: PLOS ONE Staff
Published: (2015-01-01)

The Allopregnanolone Response to Acute Stress in Females: Preclinical and Clinical Studies
by: Maria Giuseppina Pisu, et al.
Published: (2022-09-01)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
by: Ashton, NJ, et al.
Published: (2019)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
by: Xie Mathew, et al.
Published: (2011-01-01)

Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function
by: Iwamoto Sean, et al.
Published: (2006-11-01)

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
by: Georg M Kerbler, et al.
Published: (2015-01-01)

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
by: Daniel J. Norton, et al.
Published: (2020-08-01)

Allopregnanolone in Postpartum Depression
by: Graziano Pinna, et al.
Published: (2022-04-01)

2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease.
by: Jia Yao, et al.
Published: (2011-01-01)

Trajectories of Allopregnanolone and Allopregnanolone to Progesterone Ratio across the Six Subphases of Menstrual Cycle
by: Ajna Hamidovic, et al.
Published: (2023-04-01)

Chronic-Antibiotics Induced Gut Microbiota Dysbiosis Rescues Memory Impairment and Reduces β-Amyloid Aggregation in a Preclinical Alzheimer’s Disease Model
by: Paola C. Bello-Medina, et al.
Published: (2022-07-01)

Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation
by: Annie M. Racine, et al.
Published: (2014-01-01)

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease
by: Pratishtha Chatterjee, et al.
Published: (2019-10-01)

Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer’s Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia
by: Chang Shan, et al.
Published: (2023-02-01)

Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes
by: Adam C. Raikes, et al.
Published: (2022-01-01)

Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer’s disease
by: Olivia L. Hampton, et al.
Published: (2020-01-01)

Immunization with amyloid-β using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology
by: Kevin A. DaSilva, et al.
Published: (2006-08-01)

Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-β peptide levels in vivo
by: Veronica Hirsch-Reinshagen, et al.
Published: (2007-04-01)

Mitochondrial β-amyloid in Alzheimer's disease.
by: Borger, E, et al.
Published: (2011)

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
by: Pernille L. Kjeldsen, et al.
Published: (2022-01-01)

Biosynthesis and biological action of pineal allopregnanolone
by: Kazuyoshi eTsutsui, et al.
Published: (2014-05-01)

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer’s Disease
by: Luana Cristina Camargo, et al.
Published: (2021-06-01)

Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease.
by: Deborah A Roby, et al.
Published: (2019-01-01)

Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease.
by: Jia-Ying Chuang, et al.
Published: (2012-01-01)

Regional pattern of beta-amyloid accumulation in the preclinical and clinical states of Alzheimer’s disease
by: A. G. Vlassenko, et al.
Published: (2017-02-01)

Beta-amyloid and Cortical Thickness Reveal Racial Disparities in Preclinical Alzheimer's Disease
by: Ian M. McDonough
Published: (2017-01-01)

Biology of Aβ Amyloid in Alzheimer's Disease
by: Thomas Wisniewski, et al.
Published: (1997-01-01)

Reduced CSF Water Influx in Alzheimer's Disease Supporting the β-Amyloid Clearance Hypothesis.
by: Yuji Suzuki, et al.
Published: (2015-01-01)

Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression
by: Sarah A. Rudzinskas, et al.
Published: (2023-06-01)

Allopregnanolone and Neuroinflammation: a Focus on Multiple Sclerosis
by: Farshid eNoorbakhsh, et al.
Published: (2014-06-01)

Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
by: Samantha Meltzer-Brody, et al.
Published: (2020-05-01)

Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques
by: Tadafumi Hashimoto, et al.
Published: (2020-12-01)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
by: Philip S. Insel, et al.
Published: (2017-05-01)

Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease
by: Lin Nan, et al.
Published: (2011-06-01)

Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease.
by: Samuel O Adeosun, et al.
Published: (2012-01-01)

Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer’s disease
by: Sahana Srinivasan, et al.
Published: (2024-01-01)